United Therapeutics CorporationUTHR

Where UTHR's Net Debt / EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$543.15+10.03 (+1.88%)Previous close
NASDAQHealthcare

UTHR Net Debt / EBITDA: current value, 10-year range and year-by-year history

Net Debt / EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
UTHR Net Debt / EBITDA historyUTHR Net Debt / EBITDA from Dec 2023 to Jun 2026: low -1.08, high -0.39, latest -1.08.-1.13-0.93-0.73-0.53-0.33Dec 23Jun 24Dec 24Jun 25Dec 25Jun 26med -0.74

UTHR Net Debt / EBITDA by year

Yearly range of UTHR’s net debt / ebitda from 2016 to 2026. Over the full period it ranged from -4.4 to 0.2, averaging -0.6.

UTHR Net Debt / EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
2026-1.1-0.9-0.6-1.1
2025-1.0-0.9-0.6-0.8
2024-0.8-0.7-0.5-0.8
2023-0.4-0.3-0.2-0.4
2022-0.2-0.10.0-0.2
2021-0.2-0.2-0.1-0.1
2020-0.10.10.20.1
2019-4.4-2.4-0.9-0.9
2018-0.6-0.5-0.5-0.5
2017-1.1-0.8-0.4-0.4
2016-0.9-0.9-0.9-0.9

Get notified when UTHR Net Debt / EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

How many years of operating earnings it would take to pay off the company's net debt. The most common leverage ratio — higher means more financial risk and less flexibility.

Formula(Total Debt − Cash) / EBITDA
Full guide
How to read this chart

Watch the trend more than the level. Declining ratio = deleveraging, growing financial flexibility. Rising ratio = increasing leverage, which constrains dividends, buybacks, and future investment.

Key caveats
  • Sector context is essential: 3× is aggressive for a consumer brand but normal for a regulated utility. Always compare to sector peers.
  • Large acquisitions spike the ratio temporarily — check whether the integration plan credibly drives paydown.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.